Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer
Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bloem, Lourens T. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2016 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rare Cancers and Therapy - [Tarpoley] : Springer Healthcare, 2013, 4(2016), 1 vom: 11. Mai, Seite 103-116 |
|---|---|
| Übergeordnetes Werk: |
volume:4 ; year:2016 ; number:1 ; day:11 ; month:05 ; pages:103-116 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40487-016-0020-4 |
|---|
| Katalog-ID: |
SPR036522910 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036522910 | ||
| 003 | DE-627 | ||
| 005 | 20230519204135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40487-016-0020-4 |2 doi | |
| 035 | |a (DE-627)SPR036522910 | ||
| 035 | |a (SPR)s40487-016-0020-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bloem, Lourens T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2016 | ||
| 520 | |a Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. | ||
| 650 | 4 | |a Colorectal cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mode of administration |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient involvement |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Treatment choice |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a De Abreu Lourenço, Richard |4 aut | |
| 700 | 1 | |a Chin, Melvin |4 aut | |
| 700 | 1 | |a Ly, Brett |4 aut | |
| 700 | 1 | |a Haas, Marion |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rare Cancers and Therapy |d [Tarpoley] : Springer Healthcare, 2013 |g 4(2016), 1 vom: 11. Mai, Seite 103-116 |w (DE-627)815914717 |w (DE-600)2806675-3 |x 2195-6022 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2016 |g number:1 |g day:11 |g month:05 |g pages:103-116 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40487-016-0020-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2016 |e 1 |b 11 |c 05 |h 103-116 | ||
| author_variant |
l t b lt ltb a l r d alr alrd m c mc b l bl m h mh |
|---|---|
| matchkey_str |
article:21956022:2016----::atripcigramncociteislntetet |
| hierarchy_sort_str |
2016 |
| publishDate |
2016 |
| allfields |
10.1007/s40487-016-0020-4 doi (DE-627)SPR036522910 (SPR)s40487-016-0020-4-e DE-627 ger DE-627 rakwb eng Bloem, Lourens T. verfasserin aut Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2016 Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 De Abreu Lourenço, Richard aut Chin, Melvin aut Ly, Brett aut Haas, Marion aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 4(2016), 1 vom: 11. Mai, Seite 103-116 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:4 year:2016 number:1 day:11 month:05 pages:103-116 https://dx.doi.org/10.1007/s40487-016-0020-4 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 4 2016 1 11 05 103-116 |
| spelling |
10.1007/s40487-016-0020-4 doi (DE-627)SPR036522910 (SPR)s40487-016-0020-4-e DE-627 ger DE-627 rakwb eng Bloem, Lourens T. verfasserin aut Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2016 Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 De Abreu Lourenço, Richard aut Chin, Melvin aut Ly, Brett aut Haas, Marion aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 4(2016), 1 vom: 11. Mai, Seite 103-116 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:4 year:2016 number:1 day:11 month:05 pages:103-116 https://dx.doi.org/10.1007/s40487-016-0020-4 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 4 2016 1 11 05 103-116 |
| allfields_unstemmed |
10.1007/s40487-016-0020-4 doi (DE-627)SPR036522910 (SPR)s40487-016-0020-4-e DE-627 ger DE-627 rakwb eng Bloem, Lourens T. verfasserin aut Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2016 Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 De Abreu Lourenço, Richard aut Chin, Melvin aut Ly, Brett aut Haas, Marion aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 4(2016), 1 vom: 11. Mai, Seite 103-116 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:4 year:2016 number:1 day:11 month:05 pages:103-116 https://dx.doi.org/10.1007/s40487-016-0020-4 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 4 2016 1 11 05 103-116 |
| allfieldsGer |
10.1007/s40487-016-0020-4 doi (DE-627)SPR036522910 (SPR)s40487-016-0020-4-e DE-627 ger DE-627 rakwb eng Bloem, Lourens T. verfasserin aut Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2016 Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 De Abreu Lourenço, Richard aut Chin, Melvin aut Ly, Brett aut Haas, Marion aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 4(2016), 1 vom: 11. Mai, Seite 103-116 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:4 year:2016 number:1 day:11 month:05 pages:103-116 https://dx.doi.org/10.1007/s40487-016-0020-4 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 4 2016 1 11 05 103-116 |
| allfieldsSound |
10.1007/s40487-016-0020-4 doi (DE-627)SPR036522910 (SPR)s40487-016-0020-4-e DE-627 ger DE-627 rakwb eng Bloem, Lourens T. verfasserin aut Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2016 Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 De Abreu Lourenço, Richard aut Chin, Melvin aut Ly, Brett aut Haas, Marion aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 4(2016), 1 vom: 11. Mai, Seite 103-116 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:4 year:2016 number:1 day:11 month:05 pages:103-116 https://dx.doi.org/10.1007/s40487-016-0020-4 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 4 2016 1 11 05 103-116 |
| language |
English |
| source |
Enthalten in Rare Cancers and Therapy 4(2016), 1 vom: 11. Mai, Seite 103-116 volume:4 year:2016 number:1 day:11 month:05 pages:103-116 |
| sourceStr |
Enthalten in Rare Cancers and Therapy 4(2016), 1 vom: 11. Mai, Seite 103-116 volume:4 year:2016 number:1 day:11 month:05 pages:103-116 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Colorectal cancer Mode of administration Patient involvement Treatment choice |
| isfreeaccess_bool |
true |
| container_title |
Rare Cancers and Therapy |
| authorswithroles_txt_mv |
Bloem, Lourens T. @@aut@@ De Abreu Lourenço, Richard @@aut@@ Chin, Melvin @@aut@@ Ly, Brett @@aut@@ Haas, Marion @@aut@@ |
| publishDateDaySort_date |
2016-05-11T00:00:00Z |
| hierarchy_top_id |
815914717 |
| id |
SPR036522910 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036522910</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204135.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40487-016-0020-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036522910</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40487-016-0020-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bloem, Lourens T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colorectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mode of administration</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patient involvement</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment choice</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Abreu Lourenço, Richard</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chin, Melvin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ly, Brett</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, Marion</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Rare Cancers and Therapy</subfield><subfield code="d">[Tarpoley] : Springer Healthcare, 2013</subfield><subfield code="g">4(2016), 1 vom: 11. Mai, Seite 103-116</subfield><subfield code="w">(DE-627)815914717</subfield><subfield code="w">(DE-600)2806675-3</subfield><subfield code="x">2195-6022</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:11</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:103-116</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40487-016-0020-4</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">11</subfield><subfield code="c">05</subfield><subfield code="h">103-116</subfield></datafield></record></collection>
|
| author |
Bloem, Lourens T. |
| spellingShingle |
Bloem, Lourens T. misc Colorectal cancer misc Mode of administration misc Patient involvement misc Treatment choice Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| authorStr |
Bloem, Lourens T. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)815914717 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2195-6022 |
| topic_title |
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer Colorectal cancer (dpeaa)DE-He213 Mode of administration (dpeaa)DE-He213 Patient involvement (dpeaa)DE-He213 Treatment choice (dpeaa)DE-He213 |
| topic |
misc Colorectal cancer misc Mode of administration misc Patient involvement misc Treatment choice |
| topic_unstemmed |
misc Colorectal cancer misc Mode of administration misc Patient involvement misc Treatment choice |
| topic_browse |
misc Colorectal cancer misc Mode of administration misc Patient involvement misc Treatment choice |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Rare Cancers and Therapy |
| hierarchy_parent_id |
815914717 |
| hierarchy_top_title |
Rare Cancers and Therapy |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)815914717 (DE-600)2806675-3 |
| title |
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| ctrlnum |
(DE-627)SPR036522910 (SPR)s40487-016-0020-4-e |
| title_full |
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| author_sort |
Bloem, Lourens T. |
| journal |
Rare Cancers and Therapy |
| journalStr |
Rare Cancers and Therapy |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
103 |
| author_browse |
Bloem, Lourens T. De Abreu Lourenço, Richard Chin, Melvin Ly, Brett Haas, Marion |
| container_volume |
4 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bloem, Lourens T. |
| doi_str_mv |
10.1007/s40487-016-0020-4 |
| title_sort |
factors impacting treatment choice in the first-line treatment of colorectal cancer |
| title_auth |
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| abstract |
Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. © The Author(s) 2016 |
| abstractGer |
Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. © The Author(s) 2016 |
| abstract_unstemmed |
Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process. © The Author(s) 2016 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer |
| url |
https://dx.doi.org/10.1007/s40487-016-0020-4 |
| remote_bool |
true |
| author2 |
De Abreu Lourenço, Richard Chin, Melvin Ly, Brett Haas, Marion |
| author2Str |
De Abreu Lourenço, Richard Chin, Melvin Ly, Brett Haas, Marion |
| ppnlink |
815914717 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40487-016-0020-4 |
| up_date |
2024-07-03T18:08:36.449Z |
| _version_ |
1803582299387723776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036522910</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204135.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40487-016-0020-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036522910</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40487-016-0020-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bloem, Lourens T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). Methods Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013 in a teaching hospital in the Sydney metropolitan area, Australia were identified using the hospital’s database $ MOSAIQ^{®} $. The electronic medical record of each patient was manually reviewed to extract factors potentially affecting treatment choice. Logistic regression was used to assess which patient and/or treatment factors could explain the choice between 5-FU or capecitabine. Where it was available in the medical correspondence, the explicit reason for the choice made was extracted. Results 170 CRC patients were included; 119 on 5-FU, and 51 on capecitabine. The odds of receiving capecitabine as a first-line treatment were positively associated with giving patients a choice in the decision (OR = 17.51, 95% CI: 5.37–57.08). Qualitative data suggest treatment choices were motivated by convenience (oral administration) and tolerability. Time from diagnosis to treatment commencement (OR = 1.02 per month, 95% CI 1.00–1.04) was also found to be positively associated with the choice of capecitabine. The odds of being treated with capecitabine were lower for patients who lived further from the treating hospital (OR = 0.22, 95% CI 0.05–0.94). Conclusion This study suggests that patient choice, favoring oral capecitabine over i.v. 5-FU, was a key factor influencing first-line treatment for CRC in this cohort. To respect their autonomy, patients should be involved in the clinical decision making process.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colorectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mode of administration</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patient involvement</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment choice</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Abreu Lourenço, Richard</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chin, Melvin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ly, Brett</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, Marion</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Rare Cancers and Therapy</subfield><subfield code="d">[Tarpoley] : Springer Healthcare, 2013</subfield><subfield code="g">4(2016), 1 vom: 11. Mai, Seite 103-116</subfield><subfield code="w">(DE-627)815914717</subfield><subfield code="w">(DE-600)2806675-3</subfield><subfield code="x">2195-6022</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:11</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:103-116</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40487-016-0020-4</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">11</subfield><subfield code="c">05</subfield><subfield code="h">103-116</subfield></datafield></record></collection>
|
| score |
7.4011354 |